8-K: Silexion Therapeutics Averts Nasdaq Delisting, Transfers to Capital Market Under Conditions

Silexion Therapeutics Corp received a favorable Nasdaq decision, allowing it to remain listed on the Nasdaq Capital Market subject to achieving $2.5 million in shareholders' equity by September 19, 2025, and addressing a potential bid price deficiency.

Summary

• Silexion Therapeutics Corp received a favorable decision from a Nasdaq hearings panel on July 7, 2025, allowing it to remain listed on Nasdaq.
• The company's ordinary shares and warrants are expected to be transferred from the Nasdaq Global Market to the Nasdaq Capital Market on July 8, 2025, continuing to trade under existing symbols SLXN and SLXNW.
• Continued listing is conditioned on fulfilling a compliance plan to achieve at least $2.5 million in shareholders' equity.
• Silexion must demonstrate compliance with the $2.5 million shareholders' equity requirement by September 19, 2025, via an Exchange Act report with a balance sheet not older than 60 days.
• The Nasdaq hearings panel will maintain jurisdiction over the company's listing status until November 18, 2025, requiring a new compliance plan if any listing rule deficiency occurs before then.
• The company disclosed a potential future deficiency related to Nasdaq Listing Rule 5550(a)(2), which may result from its bid price closing below $1.00 for 30 consecutive trading days.
• To remedy the potential bid price deficiency, Silexion expects to effect a 1-for-15 reverse share split on or about July 25, 2025, subject to shareholder approval at the reconvened annual general meeting on July 14, 2025.

Sentiment

Score: 5

Explanation: The outcome is neutral to slightly positive. While delisting was averted, the company remains in a precarious position, requiring significant financial improvements and a reverse stock split, which often signals underlying issues. The conditions imposed by Nasdaq indicate ongoing financial fragility.

Positives

• Received a favorable decision from the Nasdaq hearings panel, avoiding immediate delisting.
• Securities will remain listed on Nasdaq, albeit on the Nasdaq Capital Market.
• The company has a clear compliance plan and timeline to address listing deficiencies.

Negatives

• The company was subject to a delisting notice due to two listing deficiencies.
• The company must transfer from the Nasdaq Global Market to the Nasdaq Capital Market, which may imply a lower market tier.
• The company has a potential future deficiency related to its share bid price falling below $1.00.
• A reverse share split of 1-for-15 is proposed, which typically indicates a low share price and can be perceived negatively by investors.

Risks

• No assurance that Silexion will successfully meet the terms of its compliance plan.
• No assurance that Silexion will maintain compliance with the Equity Standard and/or all other standards for listing on the Nasdaq Capital Market even if it initially restores compliance.
• The company may not be successful in effecting transactions that raise shareholders' equity to the minimum level of $2.5 million by September 19, 2025.
• Shareholders may not approve the proposed 1-for-15 reverse share split at the reconvened annual general meeting on July 14, 2025.
• The company may encounter other difficulties in maintaining compliance with the $2.5 million minimum shareholders' equity level or other Nasdaq listing standards on an ongoing basis.

Future Outlook

Silexion Therapeutics expects to achieve at least $2.5 million in shareholders' equity by September 19, 2025, and plans to effect a 1-for-15 reverse share split around July 25, 2025, to address a potential minimum bid price deficiency, subject to shareholder approval. The company aims to maintain ongoing compliance with all Nasdaq listing rules.

Management Comments

• The company expects that following the completion of its 2025 annual general meeting, which will be reconvened on July 14, 2025, the company will effect a 1-for-15 reverse share split, which will enable the company to remedy that bid price deficiency on or about July 25, 2025.

Industry Context

This event highlights the ongoing scrutiny by Nasdaq on listed companies to maintain specific financial and operational standards. Companies in the biotechnology or pharmaceutical sector, especially those in early development stages, often face challenges in meeting listing requirements due to high R&D costs and lack of significant revenue, making compliance with equity and bid price rules critical for continued public market access.

Stakeholder Impact

• Shareholders: Avoided immediate delisting, preserving liquidity and investment value on Nasdaq. However, face a proposed 1-for-15 reverse share split, which reduces the number of shares held and can be perceived negatively. Future share price volatility and dilution risk remain if capital raise is needed.
• Employees: Continued listing provides stability for the company, potentially reducing uncertainty regarding job security.
• Customers/Suppliers: Unlikely to have direct immediate impact, but continued listing may signal ongoing operational viability.
• Creditors: Continued listing may improve the company's ability to access capital markets, potentially easing credit concerns.

Next Steps

• Transfer of securities from Nasdaq Global Market to Nasdaq Capital Market on July 8, 2025.
• Reconvened 2025 annual general meeting on July 14, 2025, for shareholder approval of the reverse share split.
• Effect a 1-for-15 reverse share split on or about July 25, 2025, subject to shareholder approval.
• Demonstrate restoration of compliance with the $2.5 million shareholders' equity requirement by September 19, 2025, in an Exchange Act report.
• If any Nasdaq listing rule deficiency occurs before November 18, 2025, submit a new compliance plan for panel review.

Key Dates

Recommendation

Keywords

Silexion Therapeutics, Nasdaq, Delisting, Listing Compliance, Shareholders Equity, Reverse Share Split, SLXN, SLXNW, Capital Market, Bid Price Deficiency, SEC Filing, 8-K